Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres
Recruiting
- Conditions
- Severe Asthma
- Registration Number
- NCT06455462
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Inclusion Criteria:<br><br> - Patients enrolled on the TPAP who received their first dose of tezepelumab between<br> 1st January 2023 and 19th July 2023<br><br> - Patients aged =18 years at index<br><br>Exclusion Criteria:<br><br> - Patients who received any biologic drug for the treatment of asthma in a clinical<br> trial at any time during the 52 weeks prior to the index date.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Annualised exacerbation rate
- Secondary Outcome Measures
Name Time Method